Fibrosis-Inflammation Lab

⌘K

Fibrosis-Inflammation Lab

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

Models
Drugs
Insights
Resources
Pathways

Company

About
Contact Us
Privacy Policy

© 2026 Fibrosis-Inflammation Lab. All rights reserved.

/

/

Nerandomilast (nerandomilast) | Accelerate Your Fibrosis Research

Home/Drugs/Nerandomilast

Nerandomilast

nerandomilast

Approved

Sponsor: Kyorin Pharmaceutical

Indication: IPF

Mechanism of Action

Phosphodiesterase 4 (PDE4) inhibitor, reduces inflammation and fibrosis

Target: PDE4

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

COMPLETEDNCT06070610

A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the Blood

Phase:PHASE1Org:Boehringer Ingelheim

COMPLETEDNCT05633862

A Study in Healthy Chinese People to Test How Different Doses of BI 1015550 Are Taken up in the Body

Phase:PHASE1Org:Boehringer Ingelheim

COMPLETEDNCT06393127

A Study in Healthy People to Compare How 2 Different High Dose Formulations of BI 1015550 Are Taken up in the Body

Phase:PHASE1Org:Boehringer Ingelheim

NOT_YET_RECRUITINGNCT07570888

This is a Trial Designed to Evaluate the Combination of Nerandomilast With Mycophenolate Across a Wide Variety of Pulmonary Fibrosis Subtypes, With the Aim of Providing Clinicians With Assurance That This is an Appropriate Therapeutic Combination.

Phase:PHASE4Org:University of British Columbia

COMPLETEDNCT05428436

A Study in Healthy People to Compare 2 Different Formulations of BI 1015550 Taken With or Without Food

Phase:PHASE1Org:Boehringer Ingelheim

View all trials on ClinicalTrials.gov

Relevant Publications (PubMed)

Nerandomilast alleviates myositis-associated interstitial lung disease by modulating the non-Smad signalling pathway and activating the cAMP-PKA-RhoA pathway.

Cui X, Li W, Chai H et al.

RMD Open2026 May 7

Beyond attenuation: a translational review of curative-intent pharmacological targets in idiopathic pulmonary fibrosis.

Mansour GK, Hajjar AW, Sukkarieh HH

Front Med (Lausanne)2026

Will the anti-fibrotic effects of Nerandomi-Last? FIBRONEER-IPF part 2.

Khor YH, Jenkins RG

Am J Respir Crit Care Med2026 Apr 4

Efficacy and safety of nerandomilast in patients with autoimmune disease-related progressive pulmonary fibrosis in the FIBRONEER-ILD trial.

Hoffmann-Vold AM, Assassi S, Cottin V et al.

Ann Rheum Dis2026 Apr 29

Circulating Biomarkers for Predicting Disease Progression in Idiopathic Pulmonary Fibrosis: Insights into Precision Medicine.

Ruenwilai P, Tajarernmuang P, Chattipakorn SC et al.

Lung2026 Apr 27

View more on PubMed

Validated Models

This drug has been validated in the following preclinical models: